Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.7%

156 terminated/withdrawn out of 1142 trials

Success Rate

80.5%

-6.0% vs industry average

Late-Stage Pipeline

2%

24 trials in Phase 3/4

Results Transparency

65%

418 of 645 completed trials have results

Key Signals

146 recruiting418 with results121 terminated35 withdrawn

Enrollment Performance

Analytics

Phase 2
452(43.2%)
N/A
301(28.7%)
Phase 1
254(24.3%)
Phase 3
20(1.9%)
Early Phase 1
16(1.5%)
Phase 4
4(0.4%)
1047Total
Phase 2(452)
N/A(301)
Phase 1(254)
Phase 3(20)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1142)

Showing 20 of 1142 trials
NCT02816697Not ApplicableCompleted

Implementation of a System-level Tobacco Treatment Intervention

Role: lead

NCT07305740Not ApplicableRecruiting

On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety

Role: lead

NCT07064798Not ApplicableRecruiting

Cryocompression for CIPN

Role: lead

NCT06026111Not ApplicableRecruiting

Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial

Role: lead

NCT06609473Not ApplicableRecruiting

Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors

Role: lead

NCT06923397Not ApplicableRecruiting

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Role: lead

NCT06710548Not ApplicableRecruiting

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Role: lead

NCT04620187Phase 2Recruiting

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Role: lead

NCT07519200Not ApplicableNot Yet Recruiting

Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention

Role: lead

NCT05535192Not ApplicableRecruiting

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Role: lead

NCT01661881Phase 2Active Not Recruiting

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Role: lead

NCT07516405Phase 1Recruiting

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

Role: collaborator

NCT07517666Not ApplicableEnrolling By Invitation

Genetic Information for Families After Tumor Testing Study

Role: collaborator

NCT05632328Phase 2Active Not Recruiting

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Role: collaborator

NCT06758102Not ApplicableRecruiting

Dance Study for Post-surgical Pain in Breast Cancer Survivors

Role: lead

NCT06303713Phase 1Active Not Recruiting

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Role: lead

NCT05281237Not ApplicableRecruiting

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Role: collaborator

NCT07516353Not ApplicableNot Yet Recruiting

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

Role: lead

NCT04569747Phase 2Active Not Recruiting

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Role: lead

NCT02873962Phase 2Active Not Recruiting

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Role: lead